News

World ADC - October 16-19, 2023 https://worldadc-usa.com/

A Dutch-American biotech is out with $65 million in Series A funding to get into the clinic with what it calls an expanded scope of the popular antibody-drug conjugates class after a decade of legwork iterating on the original click chemistry findings that led to last year’s Nobel Prize.

Read the article on Biopharmadive

By BioWorld Twelve years on from spinning out of Philips Healthcare, Tagworks Pharmaceuticals BV has raised $65 million in a series A round to take a new generation of antibody-drug conjugates (ADCs) based on click chemistry into the clinic. Read more.

By BioCentury Netherlands-based Tagworks is using click chemistry to simultaneously accomplish on-target activation of ADCs and off-target deactivation of radiopharmaceuticals. After spinning out of Philips Healthcare in 2011, the company has announced a $65 million series A round co-led by Ysios Capital and Gilde Healthcare. Download the complete article here.

Financing round led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures Unique Click-to-Release platform enables on-target activation of antibody-drug conjugates (ADCs) and immunomodulators, as well as off-target deactivation of radiopharmaceuticals Proceeds will be used to advance the lead program, a …

Tagworks congratulates Carolyn Bertozzi, Morten Meldal and Barry Sharpless with winning the Nobel Prize in Chemistry 2022 for the development of click chemistry and bioorthogonal chemistry ! Their discoveries made a massive impact on many areas of science and form the foundation of Tagworks' Click-to-Release approach. https://www.nobelprize.org/prizes/chemistry/2022/summary/  

Carolyn R. Bertozzi, Morten Meldal, and K. Barry Sharpless receive prize for their work on reactions that quickly link molecules and the application of the reactions in living cells Three scientists have won the 2022 Nobel Prize in Chemistry: Carolyn R. Bertozzi of Stanford University, Morten Meldal of the University …

Tagworks announces the completion of an investment round led by Meneldor (The Netherlands), Oost NL (The Netherlands), and a syndicate of high net-worth private investors. The proceeds of the financing will be used for the clinical development of Tagworks' lead program.    

A key patent that encompasses the therapeutic application scope of the Click-to-Release platform has been granted in the US (US 10,967,069 B2), further strengthening Tagworks’ IP portfolio. The patent titled “BIO-ORTHOGONAL DRUG ACTIVATION”, covers the invention of the pyridazine elimination reaction that underlies the Click-to-Release approach. The patent protects a …